[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alopecia-totalis-at\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alopecia-totalis-at":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100624174","phase-4-tofacitinib-vs-methotrexate-for-severe-alopecia-areata-tofa-mtx-aa-100624174",false,"NCT07406204","Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial","TOFA-MTX-AA","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nClinical diagnosis of severe alopecia areata, alopecia totalis, or alopecia universalis (as per protocol\u002Foperational definition), confirmed by a consultant dermatologist.\n\nEither sex.\n\nAble and willing to provide written informed consent.\n\nExclusion Criteria:\n\nCurrently receiving or recently used any systemic treatment intended for hair regrowth for alopecia areata (e.g., systemic corticosteroids, immunosuppressants, JAK inhibitors).\n\nPregnant women.\n\nHistory or clinical evidence of renal, hepatic, or pulmonary disease.\n\nAny condition that, in the investigator's judgment, makes participation unsafe or interferes with adherence to the study protocol.","ALL","18 Years","60 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair). Alopecia areata is an autoimmune condition that can cause significant hair loss and emotional distress.\n\nAdults aged 18 to 60 years with severe disease will be enrolled at the Department of Dermatology, MTI-Hayatabad Medical Complex, Peshawar, after ethical approval and written informed consent. Participants will be randomly assigned to receive either tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks.\n\nThe main outcome will be improvement in hair loss measured by the Severity of Alopecia Tool (SALT) score. Treatment will be considered effective if there is more than 50% improvement in SALT score from baseline at the end of 12 weeks. Safety will be monitored during follow-up visits. The findings may help guide treatment decisions for severe alopecia areata in our local population.",[28,29,30],"Alopecia Areata","Alopecia Totalis (AT)","Alopecia Universalis",[32,33,34,35,36],"Tofacitinib","Methotrexate","Janus Kinase Inhibitor","Severe Alopecia Areata","Autoimmune Hair Loss","NOT_YET_RECRUITING","2026-02-05",{"date":40,"type":41},"2026-02-12","ACTUAL",{"date":43,"type":22},"2026-02-15",{"date":45,"type":22},"2026-08-15",{"name":47,"class":48},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100622279","phase-4-cyclosporine-or-methotrexate-for-pediatric-alopecia-areata-routine-clinical-care-effectiveness-study-100622279","NCT07381556","Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study","The Effectiveness of Cyclosporine Versus Methotrexate in the Treatment of Pediatric Alopecia Areata in Routine Clinical Care: a Patient Preference Trial","COMPARE","Inclusion criteria\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Age 2-17 years\n* Clinical diagnosis of AA by a certified dermatologist\n* Willingness of participant (in case 12-17 years) and parents to provide informed consent for participation in the study.\n\nExclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.\n* Patients who are ineligible for the CsA arm (due to contraindications), are automatically included in the MTX arm.\n* Contra-indications CsA:\n\nImpaired kidney function. Poorly controlled hypertension Active infections. Presence of a malignancy. Nephrotic syndrome combined with poorly controlled hypertension, infection or malignancy.\n\nKidney disorders, except in cases of nephrotic syndrome with mild to moderate renal impairment.\n\n* Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the CsA arm.\n* Contraindications MTX:\n\nConception (both male and female) and lactation Severe kidney or liver dysfunction (fibrosis, cirrhosis) or alcohol abuse Bone marrow hypoplasia, immunodeficiency Anemia, leukopenia, or thrombocytopenia Poor nutritional status (low albumin) Hypersensitivity or allergy to MTX Lung toxicity due to MTX or significant reduction in lung function.","2 Years","17 Years",{"count":60,"type":22},50,[25],"Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata. Eligibility for this treatment, in the Netherlands, requires prior failure of systemic therapies such as cyclosporin or methotrexate. However, the choice between methotrexate and cyclosporin as first-line systemic treatment is not supported by robust comparative studies.\n\nTherefore, the investigators conduct a patient preference trial with a long-term follow-up provided in the Pediatric Systemic Alopecia Areata Registry (STA2R-Pediatric). This study will evaluate the effectiveness of Cyclosporin (CsA) and Methotrexate (MTX) in children and adolescents with moderate-to-severe AA.\n\nObjective(s): To investigate the effectiveness of CsA and MTX in the treatment of children and adolescents with alopecia areata in routine clinical care.\n\nStudy type: This is a prospective, patient preference clinical trial with a duration up to 36 weeks in accordance with the routine clinical care guidelines.\n\nStudy population: This study will include children and adolescents (2-17 years old) diagnosed with AA who start first-line systemic treatment.\n\nMethods: Patients and their parents will choose between CsA and MTX treatment as in routine clinical care, receiving follow-up in accordance with standard clinical practices. The participants will not be randomized. The primary endpoint is the measurement of the Severity of Alopecia Tool (SALT) at 9-months with a secondary endpoint at 24 weeks. SALT scores will be measured by a blinded assessor. The (Children) - Dermatology Life Quality Index ((C)-DLQI) questionnaire will be conducted at each visit (0, 3, 6, 9 months), allowing evaluation of the impact on patients' quality of life.",[64,65,66,67,29,68],"Alopecia Areata(AA)","Alopecia Areata (AA)","Alopecia Totalis\u002FUniversalis","Alopecia Universalis (AU)","Alopecia Areata (& Ophiasis)",[70,71,72],"Pediatric","Alopecia areata","systemic treatment alopecia areata","RECRUITING","2026-01-26",{"date":76,"type":41},"2026-02-02",{"date":78,"type":41},"2025-11-01",{"date":80,"type":22},"2027-11-01",{"name":82,"class":83},"Erasmus Medical Center","OTHER",1]